Add this topic to your myFT Digest for news straight to your inbox
Chief executive says customers very willing to pay for Wegovy from their own pockets
US reforms will put Big Pharma under pressure but innovative companies will retain their pricing power
Danish drugmaker reports better than expected earnings for 2023
State will be first to capitalise on rules designed to cut high costs Americans pay for drugs
The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
Preliminary probe looks into financial communications around 2017 launch of group’s blockbuster drug Dupixent
Sector has been critical of government after sharp rise in clawback tax
It follows surge in popularity of Ozempic, which is often used for weight loss
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer
Medicare’s negotiations on the cost of medicines could affect how drug research is funded globally
Efforts to rein in soaring health costs have already hit corporate shares but the sell-off looks premature
Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades
Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines
Companies say system will dent market competition for new off-patent medicines in coming years
A new study bolsters the case that semaglutide is not merely a vanity drug but has a key role to play in treating obesity
Legal and regulatory actions are more likely to drag on earnings than negate them
Pharma industry deprioritising certain pills with shorter exclusivity period, says head of Swiss drugmaker
A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise
Successful pilot in England will be expanded to more pharma companies and include N Ireland, Scotland and Wales
Pharmaceutical group says parts of law are unconstitutional
UK unveils reforms worth £650mn to boost the life sciences sector
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
International Edition